{"hands_on_practices": [{"introduction": "The foundational question in designing any clinical trial is determining the necessary number of participants. This exercise grounds the abstract concepts of Type I error ($\\alpha$), Type II error ($\\beta$), and statistical power ($1-\\beta$) in this essential, practical task. By deriving the sample size formula from first principles, you will solidify your understanding of how these error rates dictate the scope and feasibility of a study, ensuring it is adequately equipped to detect a clinically meaningful effect. [@problem_id:4992656]", "problem": "A two-arm Randomized Controlled Trial (RCT) is planned to compare an antihypertensive drug against placebo with equal allocation. The primary endpoint is the change in systolic blood pressure, measured in millimeters of mercury. Investigators will use a two-sided hypothesis test of the difference in population means with type I error rate $\\alpha = 0.05$. Assume individual patient outcomes within each arm are independent and identically distributed, approximately normal, with a common and known standard deviation $\\sigma = 10$ millimeters of mercury. The clinically meaningful difference to detect is a true mean reduction in the treatment arm relative to placebo of $\\delta = 4$ millimeters of mercury. The design target is statistical power $1 - \\beta = 0.80$.\n\nStarting from the definitions of type I error, type II error, and statistical power, and the distribution of the standardized difference in sample means under the null and under a fixed alternative, derive an expression for the required per-arm sample size for a two-sided test with equal allocation. Then compute the minimal integer number of participants per arm required to attain power at least $0.80$ for $\\delta = 4$, $\\sigma = 10$, and $\\alpha = 0.05$. Provide the final answer as a single integer giving the required per-arm sample size.", "solution": "Let $\\mu_1$ and $\\mu_2$ be the population mean changes in systolic blood pressure for the placebo and treatment arms, respectively. The sample sizes are equal, $n_1 = n_2 = n$. The outcomes are assumed to be normally distributed with a common known standard deviation $\\sigma$. The hypotheses for a two-sided test are:\n$$ H_0: \\mu_1 - \\mu_2 = 0 $$\n$$ H_a: \\mu_1 - \\mu_2 \\neq 0 $$\n\nThe test statistic is the standardized difference in sample means, $\\bar{X}_1 - \\bar{X}_2$. The sampling distribution of the difference is $\\bar{X}_1 - \\bar{X}_2 \\sim N(\\mu_1 - \\mu_2, \\frac{\\sigma^2}{n} + \\frac{\\sigma^2}{n}) = N(\\mu_1 - \\mu_2, \\frac{2\\sigma^2}{n})$.\nUnder the null hypothesis $H_0$, the test statistic is:\n$$ Z = \\frac{\\bar{X}_1 - \\bar{X}_2}{\\sqrt{\\frac{2\\sigma^2}{n}}} $$\nwhich follows a standard normal distribution, $Z \\sim N(0, 1)$.\n\nA Type I error occurs if we reject $H_0$ when it is true. For a two-sided test at a significance level $\\alpha$, we reject $H_0$ if $|Z| > z_{1-\\alpha/2}$, where $z_{1-\\alpha/2}$ is the upper $(1-\\alpha/2)$-quantile of the standard normal distribution. This defines the rejection region in terms of the observed sample difference as $|\\bar{X}_1 - \\bar{X}_2| > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}}$.\n\nA Type II error occurs if we fail to reject $H_0$ when it is false. The probability of a Type II error is $\\beta$. Statistical power, $1-\\beta$, is the probability of correctly rejecting $H_0$ when the alternative hypothesis $H_a$ is true. We calculate power for a specific alternative, namely that the true difference is the clinically meaningful difference $\\delta$. So, we assume $\\mu_1 - \\mu_2 = \\delta$.\n\nUnder this alternative, the sampling distribution is $\\bar{X}_1 - \\bar{X}_2 \\sim N(\\delta, \\frac{2\\sigma^2}{n})$. The power is the probability that the observed difference falls in the rejection region, given $\\mu_1 - \\mu_2 = \\delta$:\n$$ 1 - \\beta = P\\left(|\\bar{X}_1 - \\bar{X}_2| > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}} \\;\\middle|\\; \\mu_1 - \\mu_2 = \\delta\\right) $$\nAssuming $\\delta > 0$, the power is dominated by detections in the upper tail of the rejection region. The power can be expressed as:\n$$ 1 - \\beta = P\\left(\\bar{X}_1 - \\bar{X}_2 > z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}}\\right) + P\\left(\\bar{X}_1 - \\bar{X}_2  -z_{1-\\alpha/2}\\sqrt{\\frac{2\\sigma^2}{n}}\\right) $$\nTo evaluate this probability under $H_a$, we standardize using the mean $\\delta$:\n$$ Z' = \\frac{(\\bar{X}_1 - \\bar{X}_2) - \\delta}{\\sqrt{\\frac{2\\sigma^2}{n}}} \\sim N(0, 1) $$\nRewriting the inequalities in terms of $Z'$:\n$$ 1 - \\beta = P\\left(Z' > z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right) + P\\left(Z'  -z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right) $$\nFor typical study designs, the second term is negligible because $-z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}$ is a large negative number, making the probability extremely small. We thus proceed using the standard approximation:\n$$ 1 - \\beta \\approx P\\left(Z' > z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right) $$\nLet $\\Phi(\\cdot)$ be the cumulative distribution function of the standard normal distribution. Then $1-\\beta \\approx 1 - \\Phi\\left(z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right)$, which implies $\\beta \\approx \\Phi\\left(z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}}\\right)$.\nBy definition of normal quantiles, $z_\\beta = \\Phi^{-1}(\\beta)$. Thus:\n$$ z_\\beta = z_{1-\\alpha/2} - \\frac{\\delta}{\\sqrt{2\\sigma^2/n}} $$\nSince the standard normal distribution is symmetric about $0$, $z_\\beta = -z_{1-\\beta}$. Substituting this gives:\n$$ -z_{1-\\beta} = z_{1-\\alpha/2} - \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}} $$\nRearranging to solve for the sample size $n$:\n$$ \\frac{\\delta\\sqrt{n}}{\\sigma\\sqrt{2}} = z_{1-\\alpha/2} + z_{1-\\beta} $$\n$$ \\sqrt{n} = \\frac{\\sigma\\sqrt{2}(z_{1-\\alpha/2} + z_{1-\\beta})}{\\delta} $$\nSquaring both sides yields the desired expression for the per-arm sample size:\n$$ n = \\frac{2\\sigma^2(z_{1-\\alpha/2} + z_{1-\\beta})^2}{\\delta^2} $$\nNow, we compute the minimal integer sample size for the given parameters:\nType I error rate $\\alpha = 0.05$.\nStatistical power $1 - \\beta = 0.80$, so the Type II error rate is $\\beta = 0.20$.\nCommon standard deviation $\\sigma = 10$ mmHg.\nClinically meaningful difference $\\delta = 4$ mmHg.\n\nFirst, we find the required quantiles from the standard normal distribution:\nFor a two-sided test with $\\alpha = 0.05$, we need the upper $1 - \\alpha/2 = 1 - 0.025 = 0.975$ quantile:\n$$ z_{1-\\alpha/2} = z_{0.975} \\approx 1.960 $$\nFor a power of $0.80$, we need the upper $1 - \\beta = 0.80$ quantile:\n$$ z_{1-\\beta} = z_{0.80} \\approx 0.842 $$\nSubstituting these values into the derived formula for $n$:\n$$ n = \\frac{2(10)^2(1.960 + 0.842)^2}{(4)^2} $$\n$$ n = \\frac{2 \\times 100 \\times (2.802)^2}{16} $$\n$$ n = \\frac{200 \\times 7.851204}{16} $$\n$$ n = 12.5 \\times 7.851204 $$\n$$ n \\approx 98.14005 $$\nSince the number of participants must be an integer, and the power must be *at least* $0.80$, we must round the calculated value of $n$ up to the next whole number. Choosing $n=98$ would result in a power slightly below the target of $0.80$. Therefore, the minimal integer number of participants required per arm is $99$.", "answer": "$$ \\boxed{99} $$", "id": "4992656"}, {"introduction": "While designing a study often involves calculating the required sample size, it is equally common to evaluate a design where the sample size is constrained by practical limitations. This practice reverses the calculation to determine the statistical power for a fixed number of participants. You will compute the probability of detecting a Minimal Clinically Important Difference (MCID) and, crucially, translate this statistical result into a clinical interpretation, assessing whether the proposed study has a reasonable chance of success. [@problem_id:4992615]", "problem": "A parallel-group comparative study is being planned to evaluate whether a new therapy improves a continuous clinical endpoint relative to a control therapy. The primary endpoint is measured on a scale where the Minimal Clinically Important Difference (MCID) is defined to be $3$ units. Historical data from large registries support modeling the endpoint as approximately normally distributed with a common, known population standard deviation $\\sigma=12$ units across arms, and independent measurements across participants. The design uses equal allocation with $n_{T}=120$ participants in the treatment arm and $n_{C}=120$ participants in the control arm. The null hypothesis is $H_{0}:\\mu_{T}-\\mu_{C}=0$ and the alternative is two-sided, $H_{1}:\\mu_{T}-\\mu_{C}\\neq 0$, with a Type I error rate $\\alpha=0.05$.\n\nUsing only core definitions and first principles (Type I error, Type II error, and statistical power), and properties of independent normal samples and their sample means, compute the statistical power to detect a true mean difference equal to the MCID of $3$ units under this design. Express the power as a decimal in the interval $[0,1]$, and round your answer to four significant figures. Then, interpret the result in clinical terms (e.g., the likelihood of detecting a difference of the MCID under this design).", "solution": "The power of a statistical test is the probability, under a specified true parameter value, of rejecting the null hypothesis. Equivalently, if $\\beta$ denotes the Type II error rate (the probability of failing to reject the null hypothesis when a specified alternative is true), then power is $1-\\beta$. For a two-sample comparison of means with independent observations and a common, known standard deviation, the sampling distribution of the difference in sample means arises from properties of the normal distribution and the independence of samples.\n\nLet $\\bar{X}_{T}$ and $\\bar{X}_{C}$ denote the sample means in the treatment and control arms, respectively. Under the model assumptions, each participantâ€™s endpoint is normally distributed with mean $\\mu_{T}$ or $\\mu_{C}$ and common known standard deviation $\\sigma=12$. The sample means satisfy\n$$\n\\bar{X}_{T}\\sim \\mathcal{N}\\!\\left(\\mu_{T},\\frac{\\sigma^{2}}{n_{T}}\\right),\\qquad \\bar{X}_{C}\\sim \\mathcal{N}\\!\\left(\\mu_{C},\\frac{\\sigma^{2}}{n_{C}}\\right),\n$$\nwith independence between arms. Therefore, the difference $\\bar{X}_{T}-\\bar{X}_{C}$ is normal with mean $\\mu_{T}-\\mu_{C}$ and variance\n$$\n\\operatorname{Var}(\\bar{X}_{T}-\\bar{X}_{C})=\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}.\n$$\nDefine the test statistic\n$$\nZ=\\frac{\\bar{X}_{T}-\\bar{X}_{C}}{\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}}.\n$$\nUnder $H_{0}:\\mu_{T}-\\mu_{C}=0$, $Z$ follows a standard normal distribution, $Z\\sim \\mathcal{N}(0,1)$. For a two-sided test with Type I error $\\alpha=0.05$, the rejection region is $|Z|z_{1-\\alpha/2}$, where $z_{1-\\alpha/2}$ is the $(1-\\alpha/2)$ quantile of the standard normal distribution. Numerically, $z_{1-\\alpha/2}=\\Phi^{-1}(0.975)\\approx 1.959963984540054$, where $\\Phi$ denotes the standard normal cumulative distribution function.\n\nUnder the alternative in which the true mean difference equals the Minimal Clinically Important Difference, $\\delta=\\mu_{T}-\\mu_{C}=3$, the distribution of $Z$ is normal with mean\n$$\n\\mu_{Z}=\\frac{\\delta}{\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}}\n$$\nand unit variance. With $n_{T}=n_{C}=120$ and $\\sigma=12$,\n$$\n\\sqrt{\\frac{\\sigma^{2}}{n_{T}}+\\frac{\\sigma^{2}}{n_{C}}}=\\sigma\\sqrt{\\frac{1}{n_{T}}+\\frac{1}{n_{C}}}=12\\sqrt{\\frac{1}{120}+\\frac{1}{120}}=12\\sqrt{\\frac{2}{120}}=12\\sqrt{\\frac{1}{60}}=\\frac{12}{\\sqrt{60}}.\n$$\nHence,\n$$\n\\mu_{Z}=\\frac{3}{12/\\sqrt{60}}=\\frac{\\sqrt{60}}{4}.\n$$\nThe power is the probability, under $Z\\sim \\mathcal{N}(\\mu_{Z},1)$, that $|Z|z_{1-\\alpha/2}$:\n$$\n\\text{Power}=\\Pr\\!\\left(Zz_{1-\\alpha/2}\\right)+\\Pr\\!\\left(Z-z_{1-\\alpha/2}\\right)=\\left[1-\\Phi\\!\\left(z_{1-\\alpha/2}-\\mu_{Z}\\right)\\right]+\\Phi\\!\\left(-z_{1-\\alpha/2}-\\mu_{Z}\\right).\n$$\nSubstitute the numerical values. First, compute $\\mu_{Z}=\\sqrt{60}/4\\approx 1.9364916731037085$. Then\n$$\nz_{1-\\alpha/2}-\\mu_{Z}\\approx 1.959963984540054-1.9364916731037085\\approx 0.0234723114363455,\n$$\nand\n$$\n-z_{1-\\alpha/2}-\\mu_{Z}\\approx -1.959963984540054-1.9364916731037085\\approx -3.8964556576437625.\n$$\nEvaluate the standard normal cumulative probabilities:\n$$\n\\Phi\\!\\left(0.0234723114\\right)\\approx 0.5093546932,\\qquad \\Phi\\!\\left(-3.8964556576\\right)\\approx 0.0000486.\n$$\nTherefore,\n$$\n\\text{Power}\\approx \\left[1-0.5093546932\\right]+0.0000486\\approx 0.4906453068+0.0000486\\approx 0.4906939.\n$$\nRounded to four significant figures, the power is $0.4907$.\n\nClinical interpretation: With $n_{T}=n_{C}=120$, $\\alpha=0.05$ two-sided, and a true mean difference equal to the Minimal Clinically Important Difference of $3$ units, the probability of detecting and declaring a statistically significant difference is approximately $0.4907$. In clinical terms, this design has slightly less than even odds of detecting a difference as large as the MCID; equivalently, the Type II error rate at the MCID is approximately $1-0.4907\\approx 0.5093$. If reliably detecting the MCID is a key objective, a larger sample size or a design change would be warranted to increase the power.", "answer": "$$\\boxed{0.4907}$$", "id": "4992615"}, {"introduction": "Statistical power calculations rely on assumptions about the true effect size ($\\delta$) and data variability ($\\sigma$), which are only estimates. This advanced exercise introduces sensitivity analysis, a critical tool for assessing a trial design's robustness against the uncertainty of these planning parameters. By determining the worst-case power over a range of plausible scenarios, you will learn how to ensure a study is not just powerful under optimistic assumptions but resilient enough to succeed in the face of real-world uncertainty. [@problem_id:4992685]", "problem": "A two-arm randomized controlled trial in hypertension will compare the mean reduction in systolic blood pressure between an investigational drug and usual care. Let the true mean reduction difference be $\\delta$ (drug minus control), and assume patient-level outcomes are independently and identically distributed as normal with a common standard deviation $\\sigma$ in both arms. Equal allocation is used with $n=100$ patients per arm. The primary analysis will test the superiority null hypothesis $H_{0}:\\delta=0$ versus the two-sided alternative $H_{1}:\\delta\\neq 0$ at a Type I error rate $\\alpha=0.05$ using a large-sample Wald test based on the difference in sample means.\n\nThe design team has specified baseline planning values $\\delta_{0}=5$ (millimeters of mercury) and $\\sigma_{0}=12$ (millimeters of mercury), but acknowledges uncertainty in these parameters. To assess robustness, conduct a sensitivity analysis of statistical power with respect to simultaneous variation of $\\sigma$ and $\\delta$ by $\\pm 20\\%$ around their baselines. Specifically, treat $\\delta$ and $\\sigma$ as uncertain within the ranges $\\delta\\in[0.8\\delta_{0},\\,1.2\\delta_{0}]$ and $\\sigma\\in[0.8\\sigma_{0},\\,1.2\\sigma_{0}]$, and consider all joint combinations in these ranges.\n\nStarting from the fundamental definitions of Type I error, Type II error, and power, and from the sampling distribution of the difference in sample means under the true $\\delta\\neq 0$, derive the power as a function of $\\sigma$ and $\\delta$. Then, determine the worst-case (minimum) power over the stated joint ranges. Report that single worst-case power value as a decimal in the unitless probability scale. Round your final numerical answer to four significant figures.\n\nIn addition, briefly explain the implications of your sensitivity result for robust trial design in this medical context, grounded in first principles and without assuming any formulas not derived from those principles.", "solution": "Let $\\mu_D$ and $\\mu_C$ be the true mean reductions in systolic blood pressure for the drug and control arms, respectively. The true difference is $\\delta = \\mu_D - \\mu_C$. Let $\\bar{X}_D$ and $\\bar{X}_C$ be the sample mean reductions from the $n=100$ patients in each arm. The estimator for $\\delta$ is $\\hat{\\delta} = \\bar{X}_D - \\bar{X}_C$.\n\nFrom the problem statement, the patient-level outcomes are i.i.d. normal with a common variance $\\sigma^2$. Therefore, the sampling distributions of the sample means are $\\bar{X}_D \\sim N(\\mu_D, \\frac{\\sigma^2}{n})$ and $\\bar{X}_C \\sim N(\\mu_C, \\frac{\\sigma^2}{n})$. Because the two arms are independent, the sampling distribution of their difference, $\\hat{\\delta}$, is also normal.\nThe mean of $\\hat{\\delta}$ is $E[\\hat{\\delta}] = E[\\bar{X}_D] - E[\\bar{X}_C] = \\mu_D - \\mu_C = \\delta$.\nThe variance of $\\hat{\\delta}$ is $\\text{Var}(\\hat{\\delta}) = \\text{Var}(\\bar{X}_D) + \\text{Var}(\\bar{X}_C) = \\frac{\\sigma^2}{n} + \\frac{\\sigma^2}{n} = \\frac{2\\sigma^2}{n}$.\nThus, the sampling distribution of the estimator is $\\hat{\\delta} \\sim N(\\delta, \\frac{2\\sigma^2}{n})$.\n\nThe hypothesis test is $H_0: \\delta=0$ versus $H_1: \\delta \\neq 0$. The large-sample Wald test statistic is $Z = \\frac{\\hat{\\delta} - 0}{\\text{SE}(\\hat{\\delta})}$, where $\\text{SE}(\\hat{\\delta})$ is the standard error of the estimator. For the purposes of planning and power calculation, we use the true (or assumed) standard deviation, so $\\text{SE}(\\hat{\\delta}) = \\sqrt{\\frac{2\\sigma^2}{n}} = \\sigma\\sqrt{\\frac{2}{n}}$.\nUnder $H_0$, $\\delta=0$, so $\\hat{\\delta} \\sim N(0, \\frac{2\\sigma^2}{n})$ and the test statistic $Z = \\frac{\\hat{\\delta}}{\\sigma\\sqrt{2/n}}$ follows a standard normal distribution, $Z \\sim N(0,1)$.\n\nA Type I error is the rejection of a true null hypothesis. The specified Type I error rate is $\\alpha=0.05$. For a two-sided test, we reject $H_0$ if the test statistic falls in the tails of its null distribution. The rejection region is defined by $|Z|  z_{1-\\alpha/2}$, where $z_{1-\\alpha/2}$ is the $(1-\\alpha/2)$-quantile of the standard normal distribution. With $\\alpha=0.05$, we use $z_{1-0.025} = z_{0.975}$.\nThe rejection region for $\\hat{\\delta}$ is therefore:\n$$ |\\hat{\\delta}|  z_{0.975} \\sigma\\sqrt{\\frac{2}{n}} $$\n\nStatistical power is the probability of correctly rejecting $H_0$ when the alternative hypothesis $H_1$ is true, i.e., when $\\delta \\neq 0$. Power is $1-\\beta$, where $\\beta$ is the probability of a Type II error (failing to reject $H_0$ when it is false).\nPower is a function of the true parameters $\\delta$ and $\\sigma$.\n$$ \\text{Power}(\\delta, \\sigma) = P\\left( |\\hat{\\delta}|  z_{0.975} \\sigma\\sqrt{\\frac{2}{n}} \\;\\Bigg|\\; \\delta, \\sigma \\right) $$\nUnder the alternative hypothesis, $\\hat{\\delta} \\sim N(\\delta, \\frac{2\\sigma^2}{n})$. To calculate the probability, we standardize $\\hat{\\delta}$ under this alternative distribution. Let $Z' = \\frac{\\hat{\\delta} - \\delta}{\\sigma\\sqrt{2/n}}$. Then $Z' \\sim N(0,1)$. We can express $\\hat{\\delta}$ as $\\hat{\\delta} = \\delta + Z' \\sigma\\sqrt{\\frac{2}{n}}$.\nThe power is the probability of the union of two disjoint events:\n$$ \\text{Power}(\\delta, \\sigma) = P\\left(\\hat{\\delta}  -z_{0.975} \\sigma\\sqrt{\\frac{2}{n}}\\right) + P\\left(\\hat{\\delta}  z_{0.975} \\sigma\\sqrt{\\frac{2}{n}}\\right) $$\nSubstituting $\\hat{\\delta}$ in terms of $Z'$:\n$$ P\\left(\\delta + Z' \\sigma\\sqrt{\\frac{2}{n}}  -z_{0.975} \\sigma\\sqrt{\\frac{2}{n}}\\right) \\implies P\\left(Z'  -z_{0.975} - \\frac{\\delta}{\\sigma\\sqrt{2/n}}\\right) $$\n$$ P\\left(\\delta + Z' \\sigma\\sqrt{\\frac{2}{n}}  z_{0.975} \\sigma\\sqrt{\\frac{2}{n}}\\right) \\implies P\\left(Z'  z_{0.975} - \\frac{\\delta}{\\sigma\\sqrt{2/n}}\\right) $$\nLet $\\Phi$ be the cumulative distribution function (CDF) of the standard normal distribution. Power is given by:\n$$ \\text{Power}(\\delta, \\sigma) = \\Phi\\left(-z_{0.975} - \\frac{\\delta}{\\sigma\\sqrt{2/n}}\\right) + \\left[1 - \\Phi\\left(z_{0.975} - \\frac{\\delta}{\\sigma\\sqrt{2/n}}\\right)\\right] $$\nUsing the symmetry property $\\Phi(-x) = 1 - \\Phi(x)$, the second term becomes $\\Phi\\left(-z_{0.975} + \\frac{\\delta}{\\sigma\\sqrt{2/n}}\\right)$. The power function is symmetric with respect to $\\delta$, so we can use $|\\delta|$:\n$$ \\text{Power}(\\delta, \\sigma) = \\Phi\\left(\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{0.975}\\right) + \\Phi\\left(-\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{0.975}\\right) $$\nThis is the derived expression for power.\n\nTo find the worst-case (minimum) power, we must analyze this function over the given ranges for $\\delta$ and $\\sigma$. The function $\\Phi(x)$ is monotonically increasing. The second term, $\\Phi(-\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{0.975})$, is typically negligible and its magnitude decreases as power increases. The dominant first term, $\\Phi(\\frac{|\\delta|}{\\sigma}\\sqrt{\\frac{n}{2}} - z_{0.975})$, increases with its argument. Therefore, to minimize power, we must minimize the argument of the dominant term, which is achieved by minimizing the standardized effect size, $\\frac{|\\delta|}{\\sigma}$.\n\nThe ranges are:\n$\\delta \\in [0.8\\delta_0, 1.2\\delta_0] = [0.8 \\times 5, 1.2 \\times 5] = [4, 6]$.\n$\\sigma \\in [0.8\\sigma_0, 1.2\\sigma_0] = [0.8 \\times 12, 1.2 \\times 12] = [9.6, 14.4]$.\n\nThe ratio $\\frac{|\\delta|}{\\sigma}$ (equivalent to $\\frac{\\delta}{\\sigma}$ since $\\delta > 0$) is minimized by choosing the smallest numerator and the largest denominator from their respective ranges.\nThe worst-case scenario occurs at $\\delta_{min} = 4$ and $\\sigma_{max} = 14.4$.\nWe have $n=100$ and $\\alpha=0.05$, which gives $z_{0.975} \\approx 1.959964$.\n\nThe minimized standardized effect size magnitude is $\\frac{|\\delta_{min}|}{\\sigma_{max}} = \\frac{4}{14.4} = \\frac{1}{3.6}$.\nNow we calculate the arguments for the $\\Phi$ function:\n$$ \\text{Argument 1} = \\frac{4}{14.4}\\sqrt{\\frac{100}{2}} - z_{0.975} = \\frac{1}{3.6}\\sqrt{50} - 1.959964 = \\frac{5\\sqrt{2}}{3.6} - 1.959964 \\approx 1.964185 - 1.959964 \\approx 0.004221 $$\n$$ \\text{Argument 2} = -\\frac{4}{14.4}\\sqrt{\\frac{100}{2}} - z_{0.975} = -\\frac{5\\sqrt{2}}{3.6} - 1.959964 \\approx -1.964185 - 1.959964 \\approx -3.924149 $$\nThe minimum power is:\n$$ \\text{Power}_{min} = \\Phi(0.004221) + \\Phi(-3.924149) $$\nUsing a standard normal CDF calculator:\n$$ \\Phi(0.004221) \\approx 0.501683 $$\n$$ \\Phi(-3.924149) \\approx 0.000043 $$\n$$ \\text{Power}_{min} \\approx 0.501683 + 0.000043 = 0.501726 $$\nRounding to four significant figures, the worst-case power is $0.5017$.\n\n### Implications for Robust Trial Design\nThe sensitivity analysis reveals that the statistical power of the proposed trial is highly fragile to the initial planning assumptions. While the power calculated at the baseline values ($\\delta_0=5, \\sigma_0=12$) is approximately $\\Phi(\\frac{5}{12}\\sqrt{50} - 1.96) \\approx \\Phi(0.986) \\approx 0.838$, or $84\\%$, which is conventionally acceptable, a simultaneous $20\\%$ deviation in these parameters in an unfavorable direction causes the power to plummet to the worst-case value of approximately $50\\%$.\n\nA power of $50\\%$ is equivalent to a coin toss. It means that if this less optimistic but plausible scenario were true, the trial would have only a $50/50$ chance of detecting a true therapeutic effect. From a scientific and ethical standpoint, conducting a trial with such a high risk of being inconclusive is unacceptable. It represents a waste of resources and, more importantly, exposes human subjects to the risks of an investigational drug without a reasonable probability of generating useful scientific knowledge.\n\nA robust trial design is one that maintains adequate power (e.g., $\\ge 80\\%$) across a range of plausible scenarios, not just for a single optimistic best-guess. This analysis demonstrates that the current design with $n=100$ per arm is not robust. The primary implication for the trial designers is that a larger sample size is required to buffer the study against the uncertainty in the true effect size and variability. The design must be re-calibrated to ensure sufficient power under this identified worst-case scenario, thereby increasing the overall probability of a successful and informative trial.", "answer": "$$\n\\boxed{0.5017}\n$$", "id": "4992685"}]}